Roche Molecular Systems, Inc.

Roche Sequencing Solutions, Inc.

Genia Technologies, Inc.

Roche Diagnostics Gmbh

F. Hoffmann-la Roche Ag

David Daniel Wunderlich

Shawn Lee Suko

Aruna Ayer

Mara Boenitz-Dulat

Ilya Lederman

Eileen Thai

Charles Wayan Schwab

Colin Alexander McGaw

Cleoma Arnold

Barbara Eckert

Bigna Woersdoerfer

Arkadiusz Bibillo

Tyler O'Brien Shultz

Preethi Sarvabhowman

Evan Amato

Cleoma Renetta Arnold

Tyler O'Brien Schultz

Shawn Suko

Described herein is a variant pol6 polymerase having at least one mutation selected from H223, N224, Y225, H227, I295, Y342, T343, I357, S360, L361, I363, S365Q, S366, Y367, P368, D417, E475, Y476, F478, K518, H527, T529, M531, N535, G539, P542, N545, Q546, A547, L549, I550, N552, G553, F558, A596, G603, A610, V615, Y622, C623, D624, I628, Y629, R632, N635, M641, A643, I644, T647, I648, T651, I652, K655, W656, D657, V658, H660, F662, L690 and combinations thereof.

Polymerase variants

The present disclosure provides variant Pol6 polymerase polypeptides, compositions comprising the Pol6 variant polypeptides, and methods for using the variant Pol6 polypeptides for determining the sequencing of nucleic acids, for example, by nanopore sequencing. The variant Pol6 polymerases possess decreased rates of dissociation of template from the polymerase-template complex, which result in increased processivity relative to the parental Pol6 polypeptides from which they are derived.

Pol6 polymerase variants

Described herein is a variant pol6 polymerase having at least one mutation selected from H223, N224, Y225, H227, I295, Y342, T343, I357, S360, L361, I363, S365Q, S366, Y367, P368, D417, E475, Y476, F478, K518, H527, T529, M531, N535, G539, P542, N545, Q546, A547, L549, I550, N552, G553, F558, A596, G603, A610, V615, Y622, C623, D624, I628, Y629, R632, N635, M641, A643, 1644, T647, I648, T651, I652, K655, W656, D657, V658, H660, F662, L690 and combinations thereof.

Described herein are variant pol6 polymerase having at least having at least two substitutions, wherein at least one of the substitutions is at position S366 of SEQ ID NO: 2. The disclosed polymerases may be coupled to alpha-hemolysin nanopores, and may be used in nanopore-based sequencing apparatuses.

Growing community of inventors

Penzberg, Germany

David Daniel Wunderlich